Overview

Study of SANGUINATE™ Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients

Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the safety of SANGUINATE™ versus Hydroxyurea in patients suffering from Sickle Cell Disease.
Phase:
Phase 1
Details
Lead Sponsor:
Prolong Pharmaceuticals
Treatments:
Hydroxyurea